Peter Atadja

17.0k total citations · 2 hit papers
150 papers, 11.2k citations indexed

About

Peter Atadja is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Peter Atadja has authored 150 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Molecular Biology, 36 papers in Hematology and 26 papers in Oncology. Recurrent topics in Peter Atadja's work include Histone Deacetylase Inhibitors Research (111 papers), Protein Degradation and Inhibitors (44 papers) and Epigenetics and DNA Methylation (36 papers). Peter Atadja is often cited by papers focused on Histone Deacetylase Inhibitors Research (111 papers), Protein Degradation and Inhibitors (44 papers) and Epigenetics and DNA Methylation (36 papers). Peter Atadja collaborates with scholars based in United States, Switzerland and China. Peter Atadja's co-authors include Kapil N. Bhalla, Warren Fiskus, Purva Bali, Ricky W. Johnstone, Leigh Ellis, Lin Gao, Folkert W. Asselbergs, Maria A. Cueto, Karl Riabowol and Fei Guo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Peter Atadja

148 papers receiving 11.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

2005 644 citations Warren Fiskus, Peter Atadja et al. profile →
Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family

2002 552 citations Peter Atadja et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Atadja United States	58	9.5k	2.6k	1.8k	910	770	150	11.2k
Richard B. Lock Australia	53	5.1k 0.5×	2.8k 1.1×	1.6k 0.9×	1.2k 1.3×	1.0k 1.3×	260	8.7k
Atanasio Pandiella Spain	57	6.6k 0.7×	4.9k 1.9×	1.4k 0.8×	1.5k 1.7×	1.3k 1.6×	284	11.6k
Aviv Gazit Israel	45	5.3k 0.6×	3.3k 1.3×	1.0k 0.6×	913 1.0×	1.3k 1.7×	99	9.7k
David C. Seldin United States	69	9.8k 1.0×	2.9k 1.1×	1.7k 0.9×	961 1.1×	1.4k 1.9×	202	12.5k
Mohamed Rahmani United States	47	3.9k 0.4×	1.4k 0.5×	1.2k 0.7×	554 0.6×	586 0.8×	95	5.7k
Joseph Lotem Israel	50	5.7k 0.6×	3.2k 1.2×	1.9k 1.1×	1.2k 1.3×	2.2k 2.8×	111	9.4k
Mark A. Dawson Australia	33	5.7k 0.6×	1.3k 0.5×	1.2k 0.6×	1.2k 1.3×	700 0.9×	86	7.5k
Mónica L. Guzmán United States	40	4.2k 0.4×	2.2k 0.9×	2.2k 1.2×	1.7k 1.9×	1.1k 1.4×	150	7.4k
Joel Johansson United States	34	4.3k 0.4×	1.8k 0.7×	1.1k 0.6×	512 0.6×	739 1.0×	93	6.0k
Murray D. Norris Australia	46	4.8k 0.5×	3.1k 1.2×	644 0.4×	1.6k 1.7×	559 0.7×	197	8.2k

Countries citing papers authored by Peter Atadja

Since Specialization

Citations

This map shows the geographic impact of Peter Atadja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Atadja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Atadja more than expected).

Fields of papers citing papers by Peter Atadja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Atadja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Atadja. The network helps show where Peter Atadja may publish in the future.

Co-authorship network of co-authors of Peter Atadja

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Atadja. A scholar is included among the top collaborators of Peter Atadja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Atadja. Peter Atadja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Lulu, Xin Guo, Yao Wang, et al.. (2022). Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1869(2). 166600–166600. 6 indexed citations

Vidacs, Eva, Stephin J. Vervoort, Jason Li, et al.. (2017). HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors. Cancer Research. 77(10). 2594–2606. 25 indexed citations

Jiao, Yue, Mengtao Xiao, Han Han‐Zhang, et al.. (2017). FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion. eLife. 6. 26 indexed citations

Qi, Fei, Xiaoqin Yang, Hua Jiang, et al.. (2015). SETDB1 modulates PRC2 activity at developmental genes independently of H3K9 trimethylation in mouse ES cells. Genome Research. 25(9). 1325–1335. 33 indexed citations

Woods, David, Karrune Woan, Fengdong Cheng, et al.. (2013). The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Research. 23(5). 341–348. 81 indexed citations

Fiskus, Warren, Rekha Rao, Ramesh Balusu, et al.. (2012). Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells. Clinical Cancer Research. 18(22). 6227–6238. 40 indexed citations

Lemaire, Miguel, Prasoon Agarwal, Eline Menu, et al.. (2012). The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin. Clinical Cancer Research. 18(8). 2230–2239. 13 indexed citations

Rao, Rekha, Ramesh Balusu, Warren Fiskus, et al.. (2012). Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells. Molecular Cancer Therapeutics. 11(4). 973–983. 96 indexed citations

Floris, Giuseppe, Maria Dêbiec‐Rychter, Raf Sciot, et al.. (2009). High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. Clinical Cancer Research. 15(12). 4066–4076. 49 indexed citations

10.

Symanowski, James T., Nicholas J. Vogelzang, Leigh Zawel, et al.. (2009). A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL. Journal of Thoracic Oncology. 4(2). 149–160. 25 indexed citations

11.

Kaiser, Martin, Britta Lamottke, Maren Mieth, et al.. (2009). Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. European Journal Of Haematology. 84(4). 337–344. 36 indexed citations

12.

Ellis, Leigh, Yan Pan, Gordon K. Smyth, et al.. (2008). Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. Clinical Cancer Research. 14(14). 4500–4510. 244 indexed citations

13.

Yang, Yonghua, Jie Shen, Yun Tang, et al.. (2008). Role of Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell Invasion. Cancer Research. 68(12). 4833–4842. 187 indexed citations

14.

Shao, Wenlin, Joseph D. Growney, Yun Feng, et al.. (2008). Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. Cancer Research. 68. 735–735. 15 indexed citations

15.

Rosato, Roberto R., Jorge A. Almenara, Sonia C. Maggio, et al.. (2008). Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Molecular Cancer Therapeutics. 7(10). 3285–3297. 89 indexed citations

16.

Wang, Youzhen, Joseph D. Growney, Jane Cheng, et al.. (2008). Potent anticancer activity of the deacetylase inhibitor panobinostat (LBH589) in colon cancer cell lines and patient-derived primary colon cancer xenografts. Cancer Research. 68. 2442–2442. 2 indexed citations

17.

Atadja, Peter, et al.. (2004). Molecular and Cellular Basis for the Anti‐Proliferative Effects of the HDAC Inhibitor LAQ824. Novartis Foundation symposium. 259. 249–268. 29 indexed citations

18.

Lassota, Peter, Erik J. Sorensen, Rudi Bao, et al.. (2004). NVP-LBH589, a novel histone deacetylase inhibitor, activates caspase-3 and induces apoptosis of human tumor cells in vivo. Cancer Research. 64. 927–927. 2 indexed citations

19.

Weisberg, Ellen, Laurence Catley, Peter Atadja, et al.. (2004). Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia. 18(12). 1951–1963. 51 indexed citations

20.

Atadja, Peter, et al.. (1996). Regulation of Gene Expression and Transcription Factor Binding Activity during Cellular Aging. Neurosignals. 5(3). 130–138. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact